Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

The Future of Research

PV0315_TarenGromAll the innovation that is happening in research labs around the globe may come to naught if the sites, patients, and physician investigators needed to move the science forward are not a substantive part of the equation.

In this month’s cover story “Why Sites Matter,” the challenges that clinical sites encounter, including predictability of trial business, payments, and technology issues, in addition to a highly fragmented clinical trial landscape, are explored and some of the industry’s top thought leaders in this space provide their insights on how to address many of the pressing issues of today.

The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, continues to ensure sites’ voices are heard and positively influencing decisions of industry stakeholders. Christine Pierre, founder and president of SCRS has been on a mission to make sure sites are part of the Site Advocacy Group (SAG), which has expanded robustly among forward-thinking organizations. Ensuring the sites’ voices are considered within the SAG projects and protocols they are engaged in has been transformational for all stakeholders. This pioneering initiative has provided important dialogue on more than 20 initiatives between site professionals, eight industry partners, and TransCelerate BioPharma.

TransCelerate BioPharma, the nonprofit organization dedicated to improving the health of people around the world by accelerating and enhancing the research and development (R&D) of innovative new therapies, has been a game changer. The organization’s mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design, and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Amgen, Astellas Pharma, EMD Serono, (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Merck & Co., Novo Nordisk, Shionogi & Co., and UCB.

Ms. Pierre says while sites may not be the ultimate decision maker of the end products such as protocols, technology, or new processes, they are often the end user. Therefore, the site perspective is the most strategic business tactic an organization could undertake.

We applaud the unsung heros of clinical research — patients, investigators, and sites — for their part in bringing new medicines to those in need.

Taren Grom,

Editor

~~~~~~~~~~~~~~~~~~~~~~~~~

Their word…PV0916_TheirWord

Denise Myshko
Managing Editor

Clinical sites are burdened with administrative tasks that take them away from doing research and caring for patients.

Robin Robinson
Senior Editor

Before the industry can begin to move toward a commercial transformation involving streamlined processes, it needs to get its head around the need for change.

Kim Ribbink
Features Editor

Germany’s rich pharma history continues with strong government support for R&D and innovation.
~~~~~~~~~~~~~~~~~~~~~~~~~

Coming in October 2016

M&A Industry Update
The Specialty Drug Market
Advertising to the Masses
mHealth Data
Community Relations: Meaningful Connections
Market Focus: France
Showcase:  Supply Chain & Logistic Management
Showcase:  Patient Solutions

~~~~~~~~~~~~~~~~~~~~~~~~~

Masthead

Volume 16 • Number 8
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2016
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Sixteen, Number Eight

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK